PepDiana
Back to Evidence
Primary experimental recordPositive observation

PMC10249821::ACT001149

biosynthesized enfuvirtide

Evidence text

Paper-level observation

The in vitro HIV-1 infection model revealed 2.5-fold lower mean IC50 for bio-synthetic modified enfuvirtide 0.0453 μM [95% CI 0.0316–0.0650].
textConfidence: medium

Assay observation

Activity
Antiviral
Subtype
General Antiviral
Measure
other
Comparator
=
Raw observation
0.0453 μM [95% CI 0.0316–0.0650]
Normalized measurement
=0.0453 µM
Value minimum
0.0316 µM
Value maximum
0.065 µM
Target
MT-4
Assay method
Not reported by source
Sequence
Not reported by source
Standardization
insufficient information

Source publication

Thermostable chaperone-based polypeptide biosynthesis: Enfuvirtide model product quality and protocol-related impurities.

PLOS ONE · 2023

DOI 10.1371/journal.pone.0286752 PMC10249821
Parent mention

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.